Compare Crispr Therapeutics AG (CRSP) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Marathon Digital Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Marathon Digital Holdings Inc trades at $9.64 (market cap $3.74B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | MARA | |
|---|---|---|
Market Cap | $5.23B | $3.74B |
Sector | Health | Technology |
52-Week High | $76.78 | $22.84 |
52-Week Low | $44.34 | $6.73 |
Enterprise Value | $3.65B | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
MARA Holdings trades at $9.64, down 6% post-Q2 2026 results, with a bearish technical signal and negative earnings trends. The company reported a net loss of $1.31 billion in 2025, with revenue declining to $804 million in 2026. Recent news highlights a strategic pivot to AI infrastructure, but investor sentiment remains cautious amid Bitcoin mining sector weakness.
Outlook is mixed: analyst consensus targets $16.08 (67% upside), but high losses and sector volatility pose risks. The AI transition offers growth potential, yet execution challenges and persistent negative margins demand caution. Near-term pressure from missed earnings and competitive threats may limit upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
